Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 8, 2008, Pages 757-764

  De Laat, Bas ^a,b   Eckmann, Carel M ^a   Van Schagen, Marlies ^a   Meijer, Alexander B ^b   Mertens, Koen ^b,c   Van Mourik, Jan A ^a,b,d  

^a CENTRAL LABORATORY   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antiphospholipid; Beta2 glycoprotein I; Factor V Leiden; Protein C

Indexed keywords

ACTIVATED PROTEIN C; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; THROMBOPLASTIN; PHOSPHOLIPID ANTIBODY; PROTEIN C;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; SURFACE PLASMON RESONANCE; THROMBOSIS; TITRIMETRY; ACTIVATED PROTEIN C RESISTANCE; BLOOD CLOTTING; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; HUMANS; LUPUS COAGULATION INHIBITOR; PROTEIN BINDING; PROTEIN C; THROMBOSIS;

EID: 57149100983     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32830f1b85     Document Type: Article

References (22)

1. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. BMJ 1983; 287:1088-1089.
2. de Groot PG, Bouma B, Lutters BC, Derksen RH. Lupus anticoagulant in cardiovascular diseases: the role of beta2-glycoprotein I. Ann Med 2000; 32 (Suppl 1):32-36.
3. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: result of the second International Workshop For Identification of Lupus Anticoagulants. On behalf of the subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74:1597-1603.
4. Atsumi T, Amengual O, Yasuda S, Matsuura E, Koike T. Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies. Autoimmunity 2005; 38:377-381.
5. Pengo V. Antibeta2-glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndrome. J Thromb Haemost 2005; 3:1158-1159.
6. de Laat HB, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. β2-Glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104:3598-3602.
7. Simmelink MJ, Derksen RHWM, Arnout J, de Groot PG. A simple method to discriminate between beta2-glycoprotein I and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1:740-747.
8. Safa O, Esmon CT, Esmon NL. Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-beta2-glycoprotein I monoclonal antibodies. Blood 2005; 106:1629-1635.
9. Galli M, Ruggeri L, Barbui T. Differential effects of antibeta2-glycoprotein i and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91:1999-2004.
10. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 26:1453-1457.
11. Ye Z, Liu E, Higgins J, Keavney B, Lowe G, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 9511:651-658.
12. Vos HL. Inherited defects of coagulation factor V: the thrombotic side. J Thromb Haemost 2006; 4:35-40.
13. de Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93:1271-1276.
14. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
15. Horbach DA, van Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb Haemost 1996; 76:916-924.
16. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, et al. Association between the prevalence of antibodies to β2-glycoprotein i, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001; 47:1008-1015.
17. Pengo V, Thiagarajan P, Shapiro SS, Heine MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70:69-76.
18. de Laat B, Derksen RHWM, van Lummel M, Pennings MTT, de Groot PG. Pathogenic antibeta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107:1916-1924.
19. Lutters BCH, Derksen RHWM, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278:831-838.
20. Oosting JD, Derksen RHWM, Hackeng TM, van Vliet M, Preissner KT, Bouma BN, de Groot PhG. In vitro studies of antiphospholipid antibodies and its cofactor, β2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991; 66:666-671.
21. Fernández JA, Kojima K, Petäjä J, Hackeng TM, Griffin JH. Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cells Mol Dis 2000; 26:115-123.
22. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.